{"id":"romosozumab","brandName":"Evenity","genericName":"romosozumab","companyId":"amgen","companyName":"Amgen","phase":"marketed","status":"active","modality":"","aliases":[],"developmentCodes":[],"firstApprovalDate":null,"firstApprovalCountry":null,"aiSummary":"","enrichmentLevel":3,"visitCount":1,"mechanism":{"target":"Sclerostin"},"administration":{"route":"Subcutaneous"},"safety":{"boxedWarnings":["WARNING: POTENTIAL RISK OF MYOCARDIAL INFARCTION, STROKE AND CARDIOVASCULAR DEATH EVENITY may increase the risk of myocardial infarction, stroke, and cardiovascular death [see Warnings and Precautions (5.1) ] . EVENITY should not be initiated in patients who have had a myocardial infarction or stroke within the preceding year. Consider whether the benefits outweigh the risks in patients with other cardiovascular risk factors. If a patient experiences a myocardial infarction or stroke during therapy, EVENITY should be discontinued. WARNING: POTENTIAL RISK OF MYOCARDIAL INFARCTION, STROKE AND CARDIOVASCULAR DEATH See full prescribing information for complete boxed warning. EVENITY may increase the risk of myocardial infarction, stroke and cardiovascular death. ( 5.1 ) EVENITY should not be initiated in patients who have had a myocardial infarction or stroke within the preceding year. Consider whether the benefits outweigh the risks in patients with other cardiovascular risk factors. ( 5.1 ) If a patient experiences a myocardial infarction or stroke during therapy, EVENITY should be discontinued. ( 5.1 )"],"safetySignals":[{"date":"","signal":"FALL","source":"FDA FAERS","actionTaken":"699 reports"},{"date":"","signal":"FRACTURE","source":"FDA FAERS","actionTaken":"635 reports"},{"date":"","signal":"ARTHRALGIA","source":"FDA FAERS","actionTaken":"561 reports"},{"date":"","signal":"INJECTION SITE PAIN","source":"FDA FAERS","actionTaken":"519 reports"},{"date":"","signal":"OFF LABEL USE","source":"FDA FAERS","actionTaken":"460 reports"},{"date":"","signal":"BONE DENSITY ABNORMAL","source":"FDA FAERS","actionTaken":"456 reports"},{"date":"","signal":"HOSPITALISATION","source":"FDA FAERS","actionTaken":"411 reports"},{"date":"","signal":"HEADACHE","source":"FDA FAERS","actionTaken":"401 reports"},{"date":"","signal":"PRODUCT STORAGE ERROR","source":"FDA FAERS","actionTaken":"352 reports"},{"date":"","signal":"PAIN IN EXTREMITY","source":"FDA FAERS","actionTaken":"277 reports"}],"drugInteractions":[],"commonSideEffects":[{"effect":"Arthralgia","drugRate":"","severity":"common","organSystem":""},{"effect":"Headache","drugRate":"","severity":"common","organSystem":""}],"contraindications":["Hypocalcemia"],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[{"effect":"All-cause mortality","drugRate":"0.8%","severity":"serious"},{"effect":"Nonfatal serious adverse events","drugRate":"9.1%","severity":"serious"},{"effect":"Myocardial infarction","drugRate":"0.3%","severity":"serious"},{"effect":"Stroke","drugRate":"0.2%","severity":"serious"}]},"trials":["NCT06472050","NCT01059435","NCT00950950","NCT05688969","NCT01631214","NCT05101018","NCT02791516","NCT04232657","NCT04597931","NCT04800367","NCT00896532","NCT06558188","NCT06811363","NCT05058976","NCT06720350","NCT06533865","NCT05010590","NCT07384104","NCT06164795","NCT02186171","NCT05775094","NCT02016716","NCT01796301","NCT01833754","NCT07366086","NCT06079476","NCT06973109","NCT05972551","NCT07283887","NCT03432533","NCT01588509","NCT04091243","NCT01992159","NCT01825785","NCT06938152","NCT00907296","NCT04545554","NCT01101061","NCT01575834","NCT04708886","NCT04779216","NCT05067335","NCT01081678","NCT06059222"],"indications":{"approved":[{"name":"Postmenopausal osteoporosis","diseaseId":"postmenopausal-osteoporosis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"commercial":null,"patents":[],"timeline":[],"rwe":[],"competitors":[],"ownershipHistory":[],"trialDetails":[{"nctId":"NCT06472050","phase":"Phase 4","title":"Romosozumab Versus Denosumab in Patients With Glucocorticoid-induced Osteoporosis: a 2-year Extension Study of a Randomized Controlled Trial","status":"RECRUITING","sponsor":"Tuen Mun Hospital","isPivotal":false,"enrollment":63,"indication":"Osteoporosis, Glucocorticoids Toxicity","completionDate":"2026-03"},{"nctId":"NCT01059435","phase":"Phase 1","title":"A Randomized, Double-blind, Placebo-controlled, Ascending Single-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 785 in Healthy Men and Postmenopausal Wom","status":"COMPLETED","sponsor":"Amgen","isPivotal":false,"enrollment":74,"indication":"Osteopenia","completionDate":"2007-07-06"},{"nctId":"NCT00950950","phase":"Phase 1","title":"A Randomized, Double-blind, Placebo-controlled, Multiple Dose Study to Evaluate the Effect of AMG 785 on Parameters of Bone Quality of the Forearm Using pQCT in Postmenopausal Women With Low Bone Mine","status":"COMPLETED","sponsor":"Amgen","isPivotal":false,"enrollment":24,"indication":"Osteopenia","completionDate":"2010-08-19"},{"nctId":"NCT05688969","phase":"NA","title":"Mechanisms of Anabolic Osteoporosis Therapy","status":"RECRUITING","sponsor":"Massachusetts General Hospital","isPivotal":false,"enrollment":16,"indication":"Osteoporosis, Postmenopausal","completionDate":"2028-12"},{"nctId":"NCT01631214","phase":"Phase 3","title":"A Multicenter, International, Randomized, Double-blind, Alendronate-controlled Study to Determine the Efficacy and Safety of Romosozumab in the Treatment of Postmenopausal Women With Osteoporosis","status":"COMPLETED","sponsor":"Amgen","isPivotal":true,"enrollment":4093,"indication":"Postmenopausal Women With Osteoporosis","completionDate":"2017-06-29"},{"nctId":"NCT05101018","phase":"Phase 4","title":"Treatment With Romosozumab Versus Denosumab to Improve Bone Mineral Density and Architecture in Subacute SCI","status":"ACTIVE_NOT_RECRUITING","sponsor":"James J. Peters Veterans Affairs Medical Center","isPivotal":false,"enrollment":40,"indication":"Osteoporosis, Spinal Cord Injuries","completionDate":"2027-11-01"},{"nctId":"NCT02791516","phase":"Phase 3","title":"A Multicenter, Randomized, Double-blind, Placebo-controlled, Study to Compare the Efficacy and Safety of Romosozumab With Placebo in Postmenopausal South Korean Women With Osteoporosis","status":"COMPLETED","sponsor":"Amgen","isPivotal":true,"enrollment":67,"indication":"Postmenopausal Osteoporosis","completionDate":"2018-12-21"},{"nctId":"NCT04232657","phase":"Phase 2","title":"Romosozumab to Improve Bone Mineral Density and Architecture in Chronic SCI","status":"ACTIVE_NOT_RECRUITING","sponsor":"VA Office of Research and Development","isPivotal":false,"enrollment":36,"indication":"Spinal Cord Injury (=3 Years), Sublesional Bone Loss Secondary to SCI","completionDate":"2027-03-01"},{"nctId":"NCT04597931","phase":"Phase 4","title":"Evaluation of Romosozumab vs. Zoledronic Acid Effect in Patients With Spinal Cord Injury and Low Bone Mineral Density","status":"UNKNOWN","sponsor":"Sheba Medical Center","isPivotal":false,"enrollment":30,"indication":"Osteoporosis Fracture, Spinal Cord Injuries","completionDate":"2023-11-15"},{"nctId":"NCT04800367","phase":"Phase 2","title":"Romosozumab for Premenopausal Idiopathic Osteoporosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Columbia University","isPivotal":false,"enrollment":30,"indication":"Premenopausal Idiopathic Osteoporosis","completionDate":"2028-03"},{"nctId":"NCT00896532","phase":"Phase 2","title":"A Randomised, Placebo-controlled, Multi-dose Phase 2 Study to Determine the Efficacy, Safety and Tolerability of AMG 785 in the Treatment of Postmenopausal Women With Low Bone Mineral Density","status":"COMPLETED","sponsor":"Amgen","isPivotal":false,"enrollment":419,"indication":"Low Bone Mineral Density, Postmenopausal Osteoporosis","completionDate":"2016-02-18"},{"nctId":"NCT06558188","phase":"Phase 4","title":"Combined Anabolic Therapy Study","status":"RECRUITING","sponsor":"Massachusetts General Hospital","isPivotal":false,"enrollment":50,"indication":"Osteoporosis, Postmenopausal, Osteoporosis","completionDate":"2027-07-01"},{"nctId":"NCT06811363","phase":"N/A","title":"Contribution of Bone to Urine Citrate","status":"ENROLLING_BY_INVITATION","sponsor":"University of Texas Southwestern Medical Center","isPivotal":false,"enrollment":25,"indication":"Osteoporosis","completionDate":"2027-03"},{"nctId":"NCT05058976","phase":"Phase 4","title":"Innovative Approach to Geriatric Osteoporosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Susan L. Greenspan","isPivotal":false,"enrollment":184,"indication":"Osteoporosis, Osteoporosis, Postmenopausal","completionDate":"2027-03-31"},{"nctId":"NCT06720350","phase":"Phase 4","title":"Efficacy of Romosozumab and Denosumab Combined Treatment in Postmenopausal Osteoporosis Patients with Multiple Fragility Fractures","status":"NOT_YET_RECRUITING","sponsor":"Marmara University","isPivotal":false,"enrollment":60,"indication":"Osteoporosis in Post-menopausal Women","completionDate":"2026-12-15"},{"nctId":"NCT06533865","phase":"Phase 3","title":"Romosozumab as an Adjunct to Physiologic Estrogen Replacement in Adolescents and Young Adults With Functional Hypothalamic Amenorrhea","status":"RECRUITING","sponsor":"Massachusetts General Hospital","isPivotal":true,"enrollment":114,"indication":"FHA (Functional Hypothalamic Amenorrhea)","completionDate":"2029-04"},{"nctId":"NCT05010590","phase":"Phase 4","title":"Anabolic Therapy in Postmenopausal Osteoporosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","isPivotal":false,"enrollment":50,"indication":"Postmenopausal Osteoporosis","completionDate":"2027-11-01"},{"nctId":"NCT07384104","phase":"Phase 1","title":"A Randomized, Open-Label, Single-Dose, Parallel-Controlled Biosimilarity Study to Compare the Pharmacokinetics, Pharmacodynamics, Safety and Immunogenicity of SAL023 and Italy-Manufactured Evenity in ","status":"ENROLLING_BY_INVITATION","sponsor":"Shenzhen Salubris Pharmaceuticals Co., Ltd.","isPivotal":false,"enrollment":118,"indication":"Osteoporosis","completionDate":"2026-02-05"},{"nctId":"NCT06164795","phase":"N/A","title":"Efficacy of Sequential Therapies After Osteoanabolic Treatment in Postmenopausal Women With Severe Osteoporosis: the Sequential Treatment After Romosozumab and Teriparatide/Abaloparatide (START) Study","status":"RECRUITING","sponsor":"424 General Military Hospital","isPivotal":false,"enrollment":150,"indication":"Osteoporosis, Postmenopausal","completionDate":"2027-05"},{"nctId":"NCT02186171","phase":"Phase 3","title":"A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Compare the Efficacy and Safety of Romosozumab With Placebo in Men With Osteoporosis","status":"COMPLETED","sponsor":"Amgen","isPivotal":true,"enrollment":245,"indication":"Osteoporosis in Men","completionDate":"2016-04-20"},{"nctId":"NCT05775094","phase":"Phase 1","title":"A Pilot Study of Romosozumab Efficacy and Safety for the Management of Myelomarelated OsteoLytic Disease in Postmenopausal Women With Multiple Myeloma and Osteoporosis (REMOLD-MM)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","isPivotal":false,"enrollment":10,"indication":"Osteoporosis, Multiple Myeloma","completionDate":"2027-03"},{"nctId":"NCT02016716","phase":"Phase 3","title":"A Multicenter, Randomized, Multiple-dose Phase 3 Study to Evaluate the Noninferiority of Romosozumab at a 90 mg/mL Concentration Compared With a 70 mg/mL Concentration in Postmenopausal Women With Ost","status":"COMPLETED","sponsor":"Amgen","isPivotal":true,"enrollment":294,"indication":"Postmenopausal Osteoporosis","completionDate":"2014-12-08"},{"nctId":"NCT01796301","phase":"Phase 3","title":"An Open-label, Randomized, Teriparatide-controlled Study to Evaluate the Effect of Treatment With Romosozumab in Postmenopausal Women With Osteoporosis Previously Treated With Bisphosphonate Therapy","status":"COMPLETED","sponsor":"Amgen","isPivotal":true,"enrollment":436,"indication":"Postmenopausal Osteoporosis","completionDate":"2015-05-14"},{"nctId":"NCT01833754","phase":"Phase 1","title":"A Phase 1, Open-label, Single-dose Study of Romosozumab (AMG 785) Administered Subcutaneously to Healthy Subjects and Subjects With Stage 4 Renal Impairment or Stage 5 Renal Impairment Requiring Hemod","status":"COMPLETED","sponsor":"Amgen","isPivotal":false,"enrollment":24,"indication":"Osteoporosis","completionDate":"2014-02-19"},{"nctId":"NCT07366086","phase":"Phase 3","title":"Multicenter, Safety Follow-up Study to Assess Safety of Prior Treatment With Romosozumab in Children and Adolescents With Osteogenesis Imperfecta","status":"RECRUITING","sponsor":"Amgen","isPivotal":true,"enrollment":71,"indication":"Osteogenesis Imperfecta","completionDate":"2028-05-21"},{"nctId":"NCT06079476","phase":"Phase 4","title":"An Open-label, Single-arm, Multicenter Phase 4 Study to Evaluate Safety and Tolerability of Romosozumab (EVENITY® ) in Postmenopausal Women in India With Osteoporosis and a High Risk of Fracture.","status":"COMPLETED","sponsor":"Amgen","isPivotal":false,"enrollment":100,"indication":"Postmenopausal Osteoporosis","completionDate":"2025-10-18"},{"nctId":"NCT06973109","phase":"Phase 2","title":"Investigating the Efficacy of Romosozumab in Augmenting Bone Density and Muscle Mass to Enhance the Outcomes of Spine Surgery","status":"NOT_YET_RECRUITING","sponsor":"Nitin Agarwal","isPivotal":false,"enrollment":36,"indication":"Osteoporosis, Post-menopausal","completionDate":"2027-06"},{"nctId":"NCT05972551","phase":"Phase 3","title":"A Phase 3, Open-Label, Multicenter, Randomized Study to Evaluate Efficacy and Safety of Romosozumab Compared With Bisphosphonates in Children and Adolescents With Osteogenesis Imperfecta","status":"RECRUITING","sponsor":"Amgen","isPivotal":true,"enrollment":106,"indication":"Osteogenesis Imperfecta","completionDate":"2027-08-25"},{"nctId":"NCT07283887","phase":"Phase 4","title":"Romosozumab and Denosumab, Alone or Combined, in Postmenopausal Osteoporosis: A Three-Arm Randomized Pilot Trial","status":"RECRUITING","sponsor":"National Taiwan University Hospital","isPivotal":false,"enrollment":90,"indication":"Osteoporosis","completionDate":"2026-07-31"},{"nctId":"NCT03432533","phase":"Phase 3","title":"A Randomized, Multicenter, Open-label, Parallel Group Study in Postmenopausal Women With Osteoporosis to Evaluate the Noninferiority of Subject-administered Romosozumab Via Autoinjector/Pen vs Healthc","status":"COMPLETED","sponsor":"Amgen","isPivotal":true,"enrollment":283,"indication":"Post-Menopausal Osteoporosis","completionDate":"2020-01-08"},{"nctId":"NCT01588509","phase":"Phase 1","title":"An Open-label, Randomized Study to Estimate the Percent Change From Baseline in Lumbar Spine Bone Mineral Density After 3 Months of AMG 785 Administration in Postmenopausal Women With Low Bone Mineral","status":"COMPLETED","sponsor":"Amgen","isPivotal":false,"enrollment":60,"indication":"Osteoporosis","completionDate":"2012-11-21"},{"nctId":"NCT04091243","phase":"Phase 4","title":"Romosozumab Versus Denosumab for Osteoporosis in Long-term Glucocorticoid Users: an Open Randomized Controlled Trial","status":"COMPLETED","sponsor":"Tuen Mun Hospital","isPivotal":false,"enrollment":70,"indication":"Glucocorticoid-induced Osteoporosis","completionDate":"2023-11-15"},{"nctId":"NCT01992159","phase":"Phase 2","title":"A Randomized, Double-blind, Placebo-controlled, Multi-dose Phase 2 Study to Evaluate the Efficacy, Safety and Tolerability of Romosozumab in the Treatment of Japanese Women With Postmenopausal Osteopo","status":"COMPLETED","sponsor":"Amgen","isPivotal":false,"enrollment":252,"indication":"Postmenopausal Osteoporosis (PMO)","completionDate":"2015-06-17"},{"nctId":"NCT01825785","phase":"Phase 1","title":"A Randomized, Double-blind, Placebo-controlled, Ascending Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 785 in Healthy Men and Postmenopausal W","status":"COMPLETED","sponsor":"Amgen","isPivotal":false,"enrollment":48,"indication":"Postmenopausal, Osteopenia","completionDate":"2008-12-02"},{"nctId":"NCT06938152","phase":"Phase 4","title":"Effects of Cycle Therapy With Romosozumab and Denosumab 2 Years vs 1 Year Romosozumab Followed by 1 Year Denosumab in Postmenopausal Osteoporosis Patients-A Randomized Control Trial","status":"RECRUITING","sponsor":"National Taiwan University Hospital","isPivotal":false,"enrollment":70,"indication":"Osteoporosis, Osteoporosis Postmenopausal","completionDate":"2029-12-31"},{"nctId":"NCT00907296","phase":"Phase 2","title":"A Multi-center, Randomized, Double Blind, Placebo-controlled Study of AMG 785 in Skeletally Mature Adults With a Fresh Unilateral Tibial Diaphyseal Fracture Status Post Definitive Fracture Fixation Wi","status":"COMPLETED","sponsor":"Amgen","isPivotal":false,"enrollment":402,"indication":"Fracture Healing","completionDate":"2013-05-10"},{"nctId":"NCT04545554","phase":"Phase 1","title":"An Open-label, Ascending Multiple-dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Romosozumab in Children and Adolescents With Osteogenesis Imperfecta","status":"COMPLETED","sponsor":"Amgen","isPivotal":false,"enrollment":25,"indication":"Osteogenesis Imperfecta","completionDate":"2023-03-30"},{"nctId":"NCT01101061","phase":"Phase 1","title":"A Randomized, Double-blind, Placebo-controlled, Single-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 785 in Healthy Postmenopausal Japanese Women","status":"COMPLETED","sponsor":"Amgen","isPivotal":false,"enrollment":31,"indication":"Osteopenia","completionDate":"2010-11-01"},{"nctId":"NCT01575834","phase":"Phase 3","title":"A Multicenter, International, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis","status":"COMPLETED","sponsor":"Amgen","isPivotal":true,"enrollment":7180,"indication":"Postmenopausal Osteoporosis","completionDate":"2016-12-28"},{"nctId":"NCT04708886","phase":"Phase 2","title":"Effects of Romosozumab on Bone Health in Women With Spinal Cord Injury and Osteoporosis","status":"COMPLETED","sponsor":"Northwestern University","isPivotal":false,"enrollment":12,"indication":"Osteoporosis, Bone Loss","completionDate":"2024-06-10"},{"nctId":"NCT04779216","phase":"Phase 3","title":"Effects of Romosozumab on Bone Density, Markers of Bone Metabolism and Bone Microarchitecture in Women With Anorexia Nervosa: A Pilot Study","status":"COMPLETED","sponsor":"Karen Klahr Miller, MD","isPivotal":true,"enrollment":30,"indication":"Bone Density, Low, Bone Loss","completionDate":"2025-11-17"},{"nctId":"NCT05067335","phase":"Phase 3","title":"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Romosozumab Treatment in Postmenopausal Chinese Women With Osteoporosis","status":"COMPLETED","sponsor":"UCB Biopharma SRL","isPivotal":true,"enrollment":327,"indication":"Osteoporosis","completionDate":"2023-11-09"},{"nctId":"NCT01081678","phase":"Phase 2","title":"A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Determine the Efficacy, Safety, and Tolerability of AMG 785 in Adults With a Fresh Unilateral Hip Fracture, Status Post Surgical F","status":"COMPLETED","sponsor":"Amgen","isPivotal":false,"enrollment":332,"indication":"Fracture Healing","completionDate":"2013-05-10"},{"nctId":"NCT06059222","phase":"Phase 4","title":"The Optimised Use of Romozosumab Study","status":"RECRUITING","sponsor":"University of Aarhus","isPivotal":false,"enrollment":270,"indication":"Osteoporosis","completionDate":"2026-08"}],"genericFilers":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"labelChanges":[],"nice":null,"revenue":null,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2019-12-20T00:00:00.000Z","mah":"AMGEN INC","brand_name_local":null,"application_number":"BLA761062"},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"AU","regulator":"TGA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Evenity","application_number":null},{"country_code":"CH","regulator":"Swissmedic","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Evenity","application_number":null},{"country_code":"NO","regulator":"NoMA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Evenity","application_number":null},{"country_code":"IS","regulator":"IMA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Evenity","application_number":null},{"country_code":"NZ","regulator":"Medsafe","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Evenity","application_number":null},{"country_code":"AT","regulator":"AGES","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Evenity","application_number":null},{"country_code":"BE","regulator":"FAMHP","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Evenity","application_number":null},{"country_code":"BG","regulator":"BDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Evenity","application_number":null},{"country_code":"EU","regulator":"EMA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Evenity","application_number":"EMEA/H/C/004465"},{"country_code":"GB","regulator":"MHRA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Evenity","application_number":null},{"country_code":"HR","regulator":"HALMED","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Evenity","application_number":null},{"country_code":"CY","regulator":"PHS","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Evenity","application_number":null},{"country_code":"CZ","regulator":"SUKL","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Evenity","application_number":null},{"country_code":"DK","regulator":"DKMA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Evenity","application_number":null},{"country_code":"EE","regulator":"SAM","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Evenity","application_number":null},{"country_code":"FI","regulator":"Fimea","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Evenity","application_number":null},{"country_code":"FR","regulator":"ANSM","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Evenity","application_number":null},{"country_code":"DE","regulator":"BfArM","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Evenity","application_number":null},{"country_code":"GR","regulator":"EOF","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Evenity","application_number":null},{"country_code":"HU","regulator":"OGYEI","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Evenity","application_number":null},{"country_code":"IE","regulator":"HPRA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Evenity","application_number":null},{"country_code":"IT","regulator":"AIFA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Evenity","application_number":null},{"country_code":"LV","regulator":"ZVA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Evenity","application_number":null},{"country_code":"LT","regulator":"VVKT","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Evenity","application_number":null},{"country_code":"LU","regulator":"MS","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Evenity","application_number":null},{"country_code":"MT","regulator":"MMA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Evenity","application_number":null},{"country_code":"NL","regulator":"MEB","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Evenity","application_number":null},{"country_code":"PL","regulator":"URPL","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Evenity","application_number":null},{"country_code":"PT","regulator":"Infarmed","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Evenity","application_number":null},{"country_code":"RO","regulator":"ANMDMR","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Evenity","application_number":null},{"country_code":"SK","regulator":"SIDC","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Evenity","application_number":null},{"country_code":"SI","regulator":"JAZMP","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Evenity","application_number":null},{"country_code":"ES","regulator":"AEMPS","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Evenity","application_number":null},{"country_code":"SE","regulator":"MPA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Evenity","application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":11,"withResults":2},"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=romosozumab","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T01:23:03.637199+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T01:23:11.973258+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-20T01:23:02.269313+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=romosozumab","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T01:23:12.886623+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:23:01.337131+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (boxed_warning)","rawText":"WARNING: POTENTIAL RISK OF MYOCARDIAL INFARCTION, STROKE AND CARDIOVASCULAR DEATH EVENITY may increase the risk of myocardial infarction, stroke, and cardiovascular death [see Warnings and Precautions (5.1) ] . EVENITY should not be initiated in patients who have had a myocardial infarction or stroke within the preceding year. Consider whether the benefits outweigh the risks in patients with other cardiovascular risk factors. If a patient experiences a myocardial infarction or stroke during ther","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:23:01.337195+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T01:23:14.339223+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Sclerostin inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:23:13.439056+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2107874/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:23:13.346578+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"BLA761062","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:23:01.337208+00:00"}},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:23:18.700469+00:00","fieldsConflicting":0,"overallConfidence":0.95},"crossReferences":{"chemblId":"CHEMBL2107874"},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}